
|Videos|July 14, 2015
Efficacy of Onapristone in PR-Expressing Tumors
Author(s)Alexander Zukiwski, MD
Alexander Zukiwski, MD, CEO, Arno Therapeutics, Inc., discusses the efficacy of onapristone (ONA) in progesterone receptor (PR)-expressing tumors.
Advertisement
ONA was previously evaluated in women with breast cancer, and it produced positive results. Zukiwski and his team reevaluated the drug in a phase I study, believing that they solved one of its major safety issues. They recently started a phase II study in women who have recurrent and metastatic endometrial cancer.
Alexander Zukiwski, MD, CEO, Arno Therapeutics, Inc., discusses the efficacy of onapristone (ONA) in progesterone receptor (PR)-expressing tumors.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5



































